Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hussein A. Tawbi
NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma
Cancer
Cancer Research
Oncology
Melanoma Brain Metastases: An Unmet Challenge in the Era of Active Therapy
Current Oncology Reports
Oncology
Related publications
Dose Efficacy Study of Two Schedules of High-Dose Bolus Administration of Interleukin 2 and Interferon Alpha in Metastatic Melanoma
British Journal of Cancer
Cancer Research
Oncology
A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis
Hepatology
Medicine
Hepatology
Adenovector Engineered Interleukin-2 Expressing Autologous Plasma Cell Vaccination After High-Dose Chemotherapy for Multiple Myeloma - A Phase 1 Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma
Clinical Cancer Research
Cancer Research
Oncology
A Randomised Dose Escalation Study of Subcutaneous Interleukin 2 With and Without Levamisole in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma
British Journal of Cancer
Cancer Research
Oncology
High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features
PLoS ONE
Multidisciplinary
Durability of Responses in Patients With Metastatic Renal Cell Carcinoma Treated With High Dose Interleukin-2 (HD IL-2)
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
